High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension

The pathogenesis of pulmonary hypertension (PH) remains poorly understood. Vasoconstriction, although likely to be a major factor in the disease, varies between patients and studies of a variety of vasoactive substances have sometimes yielded conflicting results. Amongst these substances, alteration of the nitric oxide (NO) system has been cited as a possible pathogenic factor but both reduction and elevation of the expression of endothelial NO‐synthase (eNOS) have been reported in pulmonary vessels. The present study has used immunocytochemistry with well‐characterized antibodies to eNOS to investigate its expression in lung tissue taken at transplantation from 44 patients with PH (22 primary, 22 secondary) and 12 non‐hypertensive controls. Semi‐quantitative assessment showed that although the levels of eNOS expression in pulmonary vessels were variable within both hypertensives and controls, a statistically significant (P<0·01) reduction of immunoreactivity was found in small arterioles from hypertensives compared with controls. In contrast, consistently strong expression of eNOS was seen in the endothelium of plexiform lesions in both the primary and the secondary PH patients. Although a decrease in the NO system of patients with PH has been reported, these findings show a distinct regional distribution of the enzyme with particularly high levels in plexiform lesions, a previously unreported observation, and offer a new perspective on the disease and on the evaluation of possible novel therapeutic approaches. © 1998 John Wiley & Sons, Ltd.

[1]  S. Scherer,et al.  Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. , 1993, The Journal of biological chemistry.

[2]  F. Murad,et al.  Characterization and localization of endothelial nitric oxide synthase using specific monoclonal antibodies. , 1993, The American journal of physiology.

[3]  B. Groves,et al.  The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. , 1989, The American review of respiratory disease.

[4]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[5]  J. Jewett,et al.  Primary pulmonary hypertension as a cause of maternal death. , 1956, American journal of obstetrics and gynecology.

[6]  S. Archer,et al.  Increased endothelium-derived NO in hypertensive pulmonary circulation of chronically hypoxic rats. , 1994, Journal of applied physiology.

[7]  P. Braquet,et al.  Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. , 1991, The Journal of clinical investigation.

[8]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[9]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[10]  J. Pepper,et al.  Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension. , 1996, Thorax.

[11]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[12]  J. Polak,et al.  Decreased endothelium-dependent pulmonary vasodilator effect of calcitonin gene-related peptide in hypoxic rats contrasts with increased binding sites. , 1995, The European respiratory journal.

[13]  R. Johns,et al.  Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[14]  E. Rutishauser,et al.  Anastomoses artério-veineuses glomiques du poumon avec syndrome d’insuffisance droite et cyanose , 1950 .

[15]  R. Michel,et al.  Different distribution of plexiform lesions in primary and secondary pulmonary hypertension. , 1995, Human pathology.

[16]  Buttery Ldk Nitric oxide synthase isoenzymes in healthy and diseased mammalian tissues : an immunochemical study. , 1996 .

[17]  N. Voelkel,et al.  Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. , 1995, The European respiratory journal.

[18]  J. Wallwork,et al.  Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. , 1991, The New England journal of medicine.

[19]  B. Brundage,et al.  High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. , 1987, Circulation.

[20]  R M Nerem,et al.  Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. , 1992, The Journal of clinical investigation.

[21]  D. Harrison,et al.  Regulation of endothelial nitric oxide synthase mRNA, protein, and activity during cell growth. , 1994, The American journal of physiology.

[22]  A. Bankfalvi,et al.  Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry , 1994, The Journal of pathology.

[23]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[24]  S. Snyder,et al.  Prolonged in vivo hypoxia enhances nitric oxide synthase type I and type III gene expression in adult rat lung. , 1995, American journal of respiratory cell and molecular biology.

[25]  J. Piette,et al.  Plasma levels of thrombomodulin in pulmonary hypertension. , 1996, The American journal of medicine.

[26]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[27]  J. Polak,et al.  Endothelial nitric oxide synthase in the human placenta: regional distribution and proposed regulatory role at the feto-maternal interface. , 1994, Placenta.